

PARK CITY, UTAH • JANUARY 7-9, 2021



SUPPORT PROSPECTUS
2021 NASH-TAG CONFERENCE
THERAPEUTIC AGENTS FOR NON-ALCOHOLIC
STEATOHEPATITIS AND FIBROSIS



TABLE OF CONTENTS

- 4 Executive Summary
- 5 Course Directors/Scientific Advisory Board Committee
- 6 Agenda
- 10 2021 NASH-TAG Support Opportunities and Important Deadlines
- 11 2021 NASH-TAG Conference Sponsorship Opportunities
- 12 2021 NASH-TAG Exhibit/Sponsor Information Form
- 13 Exhibitor Registration Instructions



EXECUTIVE SUMMARY

We are proud to announce that the 2021 NASH/TAG Conference, our fifth annual conference, will be held on Thursday, January 7-9, 2021 in Park City, UT. The conference will provide attendees with an opportunity to learn from the leading researchers in NASH and liver fibrosis about innovative science and to engage in interactive discussions and share insight with others on multiple topics related to advances in the diagnosis and management of patients with NASH/NAFLD.

The NASH-TAG conference's primary objective is to meet the educational needs of research and development stakeholders and healthcare professionals who seek to improve the lives of patients with NASH/NAFLD. The conference brings together clinicians, academia, and the pharmaceutical industry to discuss identification of the appropriate patient populations, trial designs, and therapeutic endpoints, as well as the potential benefits these agents can have on patients with NASH. We believe the success of this conference is accomplished by delivering a focused scientific educational update that highlights the most clinically-relevant advances in NASH, which include the future directions in diagnostic procedures and the challenges in drug discovery and development for both NASH and liver fibrosis.

The Scientific Advisory Council of NASH-TAG is an internationally renowned group of academic researchers who help in providing comprehensive strategic planning and guidance for the educational program. These renowned experts will assist in the development of the educational content and will serve as faculty at the conference. They will address the latest clinical trial results, design updates, new pharmacological updates, and the pharmacoeconomic benefit of future treatment to the healthcare system. In addition, the faculty will focus on epidemiology, comorbidities associated with this disease, and the impact of NASH/NAFLD (natural history).

THE CONFERENCE DIRECTORS AND FACULTY CONGRATULATES THE SELECTED 2020 NASH-TAG FUTURE LEADERS IN NASH:



Veeral Ajmera, MD, MAS
 Assistant Professor of Medicine
 Medical Director of Liver Transplantation
 Division of Gastroenterology and Hepatology
 University of California, San Diego
 La Jolla, California



Alina M. Allen, MD
 Gastroenterologist
 Liver Transplant Program
 Mayo Clinic
 Boston, Massachusetts



Michelle T. Long, MD, MSc
 Assistant Professor of Medicine
 Boston University School of Medicine
 Boston, Massachusetts



Eduardo Vilar-Gómez, MD, PhD
 Assistant Research Professor of Medicine
 Indiana University School of Medicine
 Indianapolis, Indiana

2020 NASH-TAG CONFERENCE HIGHLIGHTS:


Over 255 attendees

Of those who responded to our post conference survey *over 88% were very satisfied with the conference*

Over 80% are definitely coming back to the 2021 conference

Over 95% of respondents would recommend this conference to others and plan to attend the 2021 meeting

2020 ATTENDEE DEMOGRAPHICS



COURSE DIRECTORS



Michael Charlton, MBBS, FRCP
Professor of Medicine
Chief of Hepatology,
Director Transplant Institute
University of Chicago
Chicago, IL



Stephen Harrison, MD, FAASLD
Visiting Professor of Hepatology,
Radcliffe Department of Medicine,
University of Oxford
San Antonio, TX



Rohit Loomba, MD, MHSc
Professor of Medicine and Vice Chief,
Division of Gastroenterology
Adjunct Professor, Epidemiology and Public Health
University of California, San Diego
San Diego, CA



Vlad Ratziu, MD
Professor of Hepatology
Hôpital Pitié Salpêtrière, Institute of
Cardiometabolism and Nutrition and Université
Paris, France

SCIENTIFIC ADVISORY BOARD COMMITTEE

Manal Abdelmalek, MD
Duke University
Durham, NC

Quentin Anstee, MD
Newcastle University
Newcastle-Upon-Tyne,
United Kingdom

Stephen H. Caldwell, MD
University of Virginia
Charlottesville, VA

Kenneth Cusi, MD, FACP, FACE
University of Florida
Gainesville, FL

Anna-Mae Diehl, MD
Duke University
Durham, NC

Scott Friedman, MD
Mount Sinai Hospital
New York, NY

Samuel Klein, MD
Washington University
School of Medicine
St. Louis, MO

Yuri Popov, MD, PhD
Harvard Medical School
Boston, MA

Mary Rinella, MD
Northwestern University
Feinberg School of Medicine
Chicago, IL

Arun J. Sanyal, MD
Virginia Commonwealth University
Medical Center
Richmond, VA

Detlef Schuppan
Mainz University Medical Center
Mainz, Germany

Gerald I. Shulman, MD, PhD
Yale University School of Medicine
New Haven, CT

Bart Staels, PhD
University of Lille Nord de France
Lille, France

Frank Tacke, MD, PhD
University Hospital Aachen
Aachen, Germany

Brent A. Tetri, MD
Saint Louis University Liver Center
St. Louis, MO

Vincent Wong, MD
The Chinese University of Hong Kong
Hong Kong, China

Hannele Yki-Jarvinen, MD, PhD
University of Helsinki
Helsinki, Finland

Zobair Younossi, MD
Inova Health System
Falls Church, VA

For an updated list of faculty/speakers, please visit our website:

WWW.NASH-TAG.ORG

Conference management services provided by:

Focus Medical Communications

SAMPLE AGENDA 2021 AGENDA COMING SOON!

THURSDAY

18:00 – 21:00 Welcome Reception

FRIDAY

6:45 – 7:30 Breakfast

7:30 – 8:00 The Year 2019 in Review
Michael Charlton, MBBS, FRCP
University of Chicago
Chicago, Illinois, USA

SESSION 1: LATEST CLINICAL TRIAL RESULTS

Moderators: Mary Rinella, MD – Northwestern University Feinberg School of Medicine (Chicago, Illinois, USA) and
Rohit Loomba, MD – University of California (San Diego, California, USA)

8:00 – 8:30	REGENERATE Data	Presenter: Vlad Ratziu, MD Hopital Pitié Salpêtrière, Institute of Cardiometabolism and Nutrition and Université Paris, France	Rebuttal: Stephen Caldwell, MD University of Virginia Charlottesville, Virginia, USA
8:30 – 9:00	MSDC-0602k	Presenter: Stephen Harrison, MD University of Oxford San Antonio, Texas, USA	Rebuttal: Mary Rinella, MD Northwestern University Feinberg School of Medicine Chicago, Illinois, USA
9:00 – 9:30	Seladelpar Data – NASH Phase 2	Presenter: Stephen Harrison, MD University of Oxford San Antonio, Texas, USA	Rebuttal: Brent Tetri, MD Saint Louis University School of Medicine Saint Louis, Missouri, USA
9:30 – 9:45	New Things Considered	Presenter: Rohit Loomba, MD University of California San Diego, California, USA	
9:45 – 10:20	Break – Exhibit Hall / Poster Viewing		

SAMPLE AGENDA (CONT.)

SESSION 2: THE LIVER-GUT-ADIPOSE CROSS-TALK

Moderators: Vlad Ratzu, MD – Hopital Pitié Salpetriere, Institute of Cardiometabolism and Nutrition and Universitié (Paris, France) and Rohit Loomba, MD – University of California (San Diego, California, USA)

10:20 – 10:45	FGF-21 Biology – Brain, Liver and Adipose	Steven Kliewer, PhD The University of Texas Southwestern Medical Center Dallas, Texas, USA
10:45 – 11:15	Dissecting intestinal and systemic FXR: CVD risk and liver fibrosis risk	Ron M. Evans, PhD Salk Institute for Biological Studies La Jolla, California, USA
11:15 – 12:00	Free Paper Session – 3 Oral Presentations	Moderators: Michael Charlton, MBBS, FRCP University of Chicago Chicago, Illinois, USA Stephen Harrison, MD University of Oxford San Antonio, Texas, USA
12:00 – 16:00	Interactive Dialogue on NASH Topics	

SESSION 3: DEEP INSIGHT INTO NASH TARGETS / INSULIN RESISTANCE AND LIVER FAT CONTENT

Moderators: Quentin Anstee, BSc(Hons) MB, BS, PhD – Newcastle University (Newcastle Upon Tyne, United Kingdom) and Manal Abdelmalek, MD, MPH – Duke University (Durham, North Carolina, USA)

16:00 – 16:25	Improving Insulin Resistance: A Viable Option for Treating NASH?	Hannele Yki-Jarvinen University of Helsinki Helsinki, Finland
16:25 – 16:50	Liver Fat Content: Metabolic and Clinical Correlates	Ken Cusi, MD, FACP, FACE The University of Florida Gainesville, Florida, USA

MINI DEBATES 1: Do Changes in Liver Fat Content Predict Efficacy for NASH?

17:00 – 17:30	YES	Stephen Harrison, MD University of Oxford San Antonio, Texas, USA
	NO	Arun Sanyal, MD Virgina Commonwealth University Health Richmond, Virginia, USA

SAMPLE AGENDA (CONT.)

SESSION 4: THE SEARCH FOR NEW ANTIFIBROTIC MECHANISMS

Moderators: David Brenner, MD – University of California San Diego (San Diego, California, USA) and
Edgar Charles III, MD – Bristol-Myers Squibb (Princeton, New Jersey, USA)

17:30 – 17:55	Resolution of Organ Fibrosis	Lester F. Lau, PhD University of Illinois at Chicago Chicago, Illinois, USA
17:55 – 18:20	IL-17 in Liver Fibrosis	Tatiana Kisseleya, MD University of California San Diego San Diego, California, USA
18:20 – 18:45	Cellular Mechanosensing as a Driver for Fibrosis	Vijay Shah, MD Mayo Clinic Rochester, Minnesota, USA

18:45 – 19:30 NASH Drug Pricing – How Is This Shaping Up

Moderators: Yasmeen Rahimi, PhD – Roth Capital Partners, LLC (New York, New York, USA)

SATURDAY

6:45 – 7:30 Breakfast

SESSION 5: REFINING CLINICAL TRIAL DESIGN

Moderators: Arun Sanyal, MD – Virginia Commonwealth University Health (Richmond, Virginia, USA) and
Stephen Harrison, MD – University of Oxford (San Antonio, Texas, USA)

7:30 – 7:55	Lessons Learned from Trials in NASH Cirrhosis	Michael Charlton, MD University of Chicago Chicago, Illinois, USA
-------------	---	---

MINI DEBATES 2: Is HVPG Ready for Prime Time as an Approvable End-Point?

7:55 – 8:20	NO	Arun Sanyal, MD Virginia Commonwealth University Health Richmond, Virginia, USA
	YES	Juan Gonzalez-Abraldes, MD, MMSC University of Alberta Edmonton, Alberta, Canada
8:20 – 8:45	Non-Invasive End-Points for Early Fibrosis Trials	Quentin Anstee, BSc(Hons) MBBS, PhD Newcastle University Newcastle Upon Tyne, United Kingdom
8:45 – 9:10	MRI-Based Biomarkers of Treatment Response	Rohit Loomba, MD University of California San Diego, California, USA

SAMPLE AGENDA (CONT.)

MINI DEBATES 3: Central Pathology Assessment: A Single or Several Pathologists?

9:10 – 9:35	A Single Pathologist	Vlad Ratziu, MD Hopital Pitié Salpêtrière, Institute of Cardiometabolism and Nutrition and Université Paris, France
9:35 – 10:00	More Than One for Consensual Reading	Stephen Harrison, MD University of Oxford San Antonio, Texas, USA
10:00 – 10:20	Break – Exhibit Hall / Poster Viewing	
10:20 – 10:40	Overview of Gene Silencing Approaches for Treatment of NASH Including DGATi	Sanjay Bhanot, PhD Ionis Pharmaceuticals, Inc. Carlsbad, California, USA
10:40 – 11:00	PNPLA3 and HSD17B13 Silencing as a Therapeutic Target	Stefano Romeo, MD University of Gothenburg Gothenburg, Sweden
11:00 – 11:45	Free Paper Session – Oral Presentations	Moderators: Brent Tetri, MD Saint Louis University School of Medicine St. Louis, Missouri, USA Zobair Younossi, MD Inova Health System Falls Church, Virginia, USA
11:45 – 16:00	Ala carte roundtable discussions related to drug development	

SESSION 6: NEW PHARMACOLOGICAL TARGETS

Moderators: Dean Hum, MD – Genfit (Cambridge, Massachusetts, USA)

NOVEL THERAPIES

16:00 – 16:20	HSP-siRNA Therapies	Edgar Charles III, MD Bristol-Myers Squibb Princeton, New Jersey, USA
16:20 – 16:40	Challenges in Designing ACC Inhibitors	William Esler, PhD Pfizer, Inc. New York, New York, USA
16:40 – 17:00	Dual Agonism: What is the best practice partner for GLP1	Dorte Holst, PhD Novo Nordisk Bagsvaerd, Denmark

SAMPLE AGENDA (CONT.)

SESSION 7: METABOLIC TARGETS

Moderators: Michael Charlton, MBBS, FRCP – University of Chicago (Chicago, Illinois, USA) and
Mary Rinella, MD – Northwestern University Feinberg School of Medicine (Chicago, Illinois, USA)

17:00 – 17:20	FASNi in NASH	William McCullough Sagimet Biosciences San Mateo, California, USA
17:20 – 17:40	Duodenal Mucosal Resurfacing	Juan Carlos Lopez-Talavera, MD, PhD Fractyl Laboratories Lexington, Massachusetts, USA
17:40 – 18:00	DGATi in NASH	Sanjay Bhanot, PhD Ionis Pharmaceuticals, Inc. Carlsbad, California, USA
18:00 – 18:15	Break – Exhibit Hall / Poster Viewing	
18:15 – 19:00	Free Paper Session – Oral Presentations	Moderators: Stephen Harrison, MD University of Oxford San Antonio, Texas, USA Vlad Ratziu, MD, PhD Hopital Pitié Salpetriere, Institute of Cardiometabolism and Nutrition and Université Paris, France
19:00 – 19:30	How to Enroll a NASH Study Efficiently and Effectively	Stephen Harrison, MD University of Oxford San Antonio, Texas, USA
19:30 – 20:00	Fully Quantitative Assessment of Histopathologic Lesions in NASH	Andrew Beck, MD Path AI Boston, Massachusetts, USA
20:00 – 20:05	Closing Remarks	
20:05 – 22:00	Farewell Reception	

2021 NASH-TAG SUPPORT OPPORTUNITIES AND IMPORTANT DEADLINES

SUPPORT OPPORTUNITIES

The NASH-TAG Conference offers different levels of sponsorship to support the needs of the more than 250 healthcare professionals who will attend the conference.

NASH-TAG CONFERENCE DATES

January 7-9, 2021

The Chateaux Deer Valley
7815 Royal Street East
Park City, Utah 84060
USA

IMPORTANT DEADLINES

Initial Agreement: Supporters showing interest must commit in writing by completing the "Support Opportunities" found on the last page of this prospectus.

Payment: If requested, invoices can be generated on receipt of the fully executed Letter of Agreement with payment due 60 days from the date of the signed Letter of Agreement. Please include a copy of the invoice and/or purchase order with payment.

Checks should be made payable to:
Focus Medical Communications (Tax ID 20-8216514)

Remit payment to:
Focus Medical Communications
Attn: NASH-TAG
7 Century Drive, Suite 104
Parsippany, NJ 07054

SPONSORSHIP OPPORTUNITIES

The NASH-TAG Conference has designed a comprehensive and multi-tiered corporate sponsorship program that provides benefits at every level. We are excited to announce a new annual corporate sponsorship package for the Diamond, Platinum, and Gold levels. These packages are designed for companies and organizations interested in supporting NASH-TAG on an annual basis. As a corporate sponsor, your company will be listed as the main contributor on the NASH-TAG website.

DIAMOND: \$100,000

At the NASH-TAG Conference:

- Eight (8) complementary conference registrations
- Executive board exchange: The opportunity for up to eight (8) people from your organization to meet with the NASH-TAG course directors over lunch* to discuss anything related to your product and NASH/NAFLD
- A company-sponsored industry forum*
- Eight (8) invitations to the faculty dinner
- Sponsor of the 2021 NASH-TAG Scholars Program: NASH-TAG is offering your organization the opportunity to sponsor up to 4 researchers/fellows to attend the conference under the NASH-TAG Scholars program. This program is designed as a mentorship opportunity from national experts to the next generation of NASH emerging leaders. Your support will be used for travel support and a nominal stipend for conference expenses.
- Networking Reception Sponsor
- 12-foot conference exhibit
- Two (2) promotional bag inserts in the conference bag
- Acknowledgment as a Diamond Sponsor on individual conference websites and all conference materials

* Lunch meeting on either Friday or Saturday from 12:30 - 1:30PM. First come first served. Company responsible for food and beverages.

* NASH-TAG Conference will supply the room and AV only. Company responsible for food and beverages

* Available times: Friday 1:30PM - 3:00PM | Saturday 1:30 PM - 3:00 PM

PLATINUM: \$50,000

At the NASH-TAG Conference:

- Six (6) conference registrations
- Four (4) invitations to the faculty dinner
- Networking Reception Sponsor
- 12-foot conference exhibit
- Two (2) promotional bag inserts in the conference bag
- Acknowledgment as a Platinum Sponsor on individual conference websites and all conference materials

GOLD: \$25,000

At the NASH-TAG Conference:

- Three (3) conference registrations
- Two (2) invitations to the faculty dinner
- Networking Reception Sponsor
- 6-foot conference exhibit
- One (1) promotional bag insert in the conference bag
- Acknowledgment as a Gold Sponsor on individual conference websites and all conference materials

CONFERENCE SPONSOR: \$10,000

At the NASH-TAG Conference:

- 6-foot highly visible exhibit space
- Acknowledgment as a Conference Sponsor on individual conference websites and all conference materials

To discuss conference support opportunities further, please contact:

Pablo Gabella

Sr. Director, Business Development

Focus Medical Communications

Tel: 714-869-2769

pgabella@focusmeded.com

2021 NASH-TAG EXHIBIT

SPONSOR INFORMATION FORM

TO SECURE YOUR SPONSORSHIP,
CLICK HERE
TO COMPLETE THE ONLINE FORM AND AGREEMENT

To further discuss conference support opportunities, please contact:

Pablo Gabella

Senior Director, Business Development
Focus Medical Communications

Tel: 714-890-2769

pgabella@focusmeded.com

Checks should be made payable to:

Focus Medical Communications
(Tax ID 20-8216514)

Remit payment to:

Focus Medical Communications

Attn: NASH-TAG

7 Century Drive, Suite 104

Parsippany, NJ 07054

EXHIBITOR REGISTRATION INSTRUCTIONS

Your exhibit space is contingent on receiving full payment. All additional requests (e.g., power source, internet access) will be handled between the exhibitor and the hotel. The costs will be directly charged to the exhibitor.

EXHIBIT SPACE SELECTION

The NASH-TAG conference planners will assign the exhibit location in the expo area. Please indicate on your registration form if there are any special circumstances regarding your display.

CANCELLATION POLICY

- A refund, less a handling fee of 10%, will be given for cancellations received in writing within 3 business days after the Sponsorship/Exhibitor's Agreement is completed using the online webform. After this date, no refunds will be granted unless the conference is cancelled altogether.
- If the conference is postponed and rescheduled within one year of the originally scheduled date, no refunds will be granted. However, the sponsorship/exhibitor fee shall be applied to the rescheduled conference.
- Should the conference be cancelled and does not take place within one year of the originally scheduled date, a full refund shall be granted.

LIABILITY

The Exhibitor agrees to defend, indemnify and hold harmless the conference venue Hotel, The NASH-TAG CONFERENCE and Focus Medical Communications, along with their employees, agents, representatives, and guests, from any third party claim, cause of action, liability, damage, cost or expense of any kind whatsoever arising out of or relating in any way to the Exhibitor's alleged intentional or negligent conduct during or in connection with its participation in the conference, including the reimbursement of all damages assessed and reasonable attorneys' fees and costs incurred.

INSURANCE FOR EXHIBIT ITEMS

The Exhibitor assumes all risk and financial responsibility for the loss or damage of its personal property during or related in any to the conference. The Exhibitor further acknowledges that it is responsible for insuring its personal property and that NASH-TAG CONFERENCE does not maintain any insurance coverage for that purpose. The EXHIBITOR forever releases and otherwise waives all claims against the conference venue Hotel, The NASH-TAG CONFERENCE and Focus Medical Communications, along with their employees, agents, representatives, and guests, arising out of or relating to the loss or damage of the Exhibitor's personal property.

Signature: _____ Date: _____

Print Name: _____



For more information, please visit:

WWW.NASH-TAG.ORG

Follow Us on Twitter!

@NashTagConf